Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Biomedicines

Topics

Medicine

Neuroscience

Pathology

Internal Medicine

Cognitive Neuroscience

Show all topics

DOI

10.3390/biomedicines12071430

License

CC-BY

Other Formats

PDF